NCT00693212View on ClinicalTrials.gov

Further Studies of Attention Deficit Disorder - Residual Type (RT)

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

February 28, 1986

Primary Completion Date

November 30, 1994

Study Completion Date

November 30, 1994

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

methylphenidate

Dosing was flexible and dependent on clinical judgement, AEs and treatment response.

DRUG

methylphenidate

Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day

DRUG

placebo

Dosing is identical to the MPH arm except that the pills will contain no active medication.

Trial Locations (1)

84132

Univ of Utah, School of Medicine, Mood Disorders Clinic, Salt Lake City

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Utah

OTHER

NCT00693212 - Further Studies of Attention Deficit Disorder - Residual Type (RT) | Biotech Hunter | Biotech Hunter